. home.aspx

home.aspx
   

Genocea Biosciences on Top

June 02, 2019

Despite the index’s dip, a number of NASDAQ biotech and pharma stocks still had notable share price increases last week. In particular, Genocea Biosciences (NASDAQ:GNCA) spiked on its announcement that the Journal of Clinical Oncology chose the company’s GEN-009 clinical results to be presented at the 2019 ASCO Meeting, which took place on June 1. Genocea Biosciences is focused on developing personalized cancer immunotherapies. Its ATLAS technology platform helps the company target immunotherapies based on an individual’s tumor antigen-specific T cell responses. As such, the company is advancing programs based off ATLAS, including its GEN-009 neoantigen vaccine candidate, which is in a Phase 1/2a clinical trial in a various solid tumors. The company’s other candidate, GEN-011, is a neoantigen-specific adoptive T cell therapy for which the company anticipates filing an Investigational New Drug application sometime in the first half of 2020.